Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Sayar, HamidCripe, Larry D.Saliba, Antoine N.Abu Zaid, MohammadKonig, HeikoBoswell, H. Scott2019-01-242019-01-242019-02Sayar, H., Cripe, L. D., Saliba, A. N., Abu Zaid, M., Konig, H., & Boswell, H. S. (2018). Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials. Leukemia Research, 77, pp 30-33. https://doi.org/10.1016/j.leukres.2018.12.011https://hdl.handle.net/1805/18221enPublisher Policyacute myeloid leukemiasorafenibvorinostatCombination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trialsArticle